Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 44Squamous Cell Carcinoma of Head and Neck 19Breast Neoplasms 18Lung Neoplasms 17Colorectal Neoplasms 15Neoplasms 12Neoplasm Metastasis 12Head and Neck Neoplasms 12Ovarian Neoplasms 11Small Cell Lung Carcinoma 9Recurrence 9Sarcoma 8Pancreatic Neoplasms 8Prostatic Neoplasms 7Advanced Solid Tumors 7Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 6Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Diabetes Mellitus, Insulin-Dependent, 12 6Uterine Cervical Neoplasms 5Carcinoma, Renal Cell 5Carcinoma, Hepatocellular 5Biliary Tract Neoplasms 5Mesothelioma, Malignant 4Lymphoma, Follicular 4Lymphoma 4Fallopian Tube Neoplasms 4Esophageal Neoplasms 4Cholangiocarcinoma 4

Interventions

Cyclophosphamide 56fludarabine phosphate 30Filgrastim 28Peripheral Blood Stem Cell Transplantation 27Radiotherapy 26Cyclosporine 23Busulfan 23Etoposide 21Mycophenolic Acid 20Whole-Body Irradiation 19Antilymphocyte Serum 19Methotrexate 17Methylprednisolone 15Melphalan 14Cytarabine 13Vincristine 11Tacrolimus 11Thiotepa 10Prednisone 10Cord Blood Stem Cell Transplantation 10Rituximab 9Doxorubicin 9Leucovorin 7aldesleukin 6Granulocyte Colony-Stimulating Factor 6sargramostim 5Psychiatric Rehabilitation 5Carboplatin 5Therapeutics 4Daunorubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Dendritic Cell Sarcoma, Interdigitating × durvalumab × Clear all
NCT03003520 2023-05-22

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Celgene

Phase 2 Completed
46 enrolled 20 charts
LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡